DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Infectious Disease Treatment Market in China 2016-2020" report to their offering.
The infectious disease treatment market in China is forecast to grow at a CAGR of 5.01% during the period 2016-2020.
The report covers the present scenario and the growth prospects of the infectious disease treatment market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat infectious diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.
The report, Infectious Disease Treatment Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
- F. Hoffmann-La Roche
- Gilead Sciences
- Johnson & Johnson
- Adenovir Pharma
- Celsus Therapeutics
- Eleven Biotherapeutics
- Ferrer International
- Griffin Discoveries
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: China - An overview
PART 06: Opportunities for global and local vendors
PART 07: Pipeline analysis
PART 08: Market landscape
PART 09: Market segmentation by application
PART 10: Antibacterial drugs market in China
PART 11: Antiviral drugs market in China
PART 12: Antifungal drugs market in China
PART 13: Antiparasitic drugs market in China
PART 14: Market drivers
PART 15: Impact of drivers
PART 16: Market challenges
PART 17: Impact of drivers and challenges
PART 18: Market trends
PART 19: Vendor landscape
PART 20: Appendix
PART 21: About the Author
For more information visit http://www.researchandmarkets.com/research/hpr22c/infectious.